Immuron Ltd — Regulatory Filings 2007

Jun 6, 2007

Company Announcement

ANADIS to expand clinical trial for the treatment of Inflammatory Bowel Disease with polyclonal antibodies into Tel Aviv Sourasky Medical Center Israel

Thursday 7 June 2007

Melbourne, Australia. Biotechnology company Anadis Ltd JASX:ANXI today announced it will expand its clinical trial program into the Tel Aviv Sourasky Medical Center in Tel Aviv, Israel, to explore the efficacy of its proprietary antibody formulation for the treatment of Inflammatory Bowel Disease (IBD). This trial expands upon the clinical study already underway at St. Vincent's Hospital in Melbourne, Australia.

Inflammatory Bowel Disease is a relapsing/remitting chronic disease with gastrointestinal symptoms such as diarrhoea, rectal bleeding and abdominal pain. About four million people worldwide suffer from the disease, split roughly evenly between its two manifestations - Crohn's Disease and ulcerative colitis.

Anadis Chief Executive Officer Dr Zeil Rosenberg said the trial enhances Anadis' focus on the research, development and production of polyclonal antibodies for the treatment and prevention of major diseases. Today's announcement is another milestone in Anadis' new business strategy.

The study will be led by Professor Zamir Halpern, Chief of the Medical Center's Gastroenterology Institute, and Professor Nachum Vaisman, head of the Medical Center's Clinical Nutrition Unit.

Tel Aviv Sourasky Medical Center is one of the largest hospitals in Israel, with 1,100 beds, providing specialty care to the Tel Aviv metropolitan area. It is a teaching and research center affiliated with the Sackler School of Medicine, also in Tel Aviv.

Dr Rosenberg stated: "The announcement of the proposed clinical study at this leading medical center is one of the first clear steps in Anadis' new strategy of becoming the world leader in polyclonal antibody-based products. In addition to the establishment of our US presence, we plan to conduct more research work and clinical studies at leading academic medical centers and with leading researchers worldwide.

"Our unique colostrum-based antibody manufacturing platform offer distinct advantages, including higher safety and lower costs of manufacturing compared to serum-derived antibodies, as well as the ability to develop faster antibody formulations and production scale-up. This platform has already shown its ability to raise a variety of antibodies against bacteria, viruses and toxins."

For further information contact:

Dr Zeil Rosenberg (US) - CEO

Email: zeil.r@anadis.com.au Tel: +1 201 750 4799

Dr Grant Rawlin - Head of R&D

Email: grant.r@anadis.com.au Tel: +61 3 9358 6388

Arie Nudel – Investor Relations

Email: arie.n@anadis.com.au Tel: +61 3 9358 6388

Richard Allen - Media

Email: richard@oxygenpr.com.au Tel: +61 3 9915 6341

About Anadis Limited:

Anadis Ltd (ASX: ANX) is a research-driven biotechnology company focused on antibody-based therapeutic and preventive products. Our mission is to become the leading worldwide provider of proprietary polyclonal antibody-based solutions, helping reduce disease and increase patient quality of life. We have built our platform carefully over the past ten years.

Anadis' proprietary rapid manufacturing technology has enabled it to develop a product pipeline of polyclonal antibody-based solutions to a range of important infectious and immune-mediated diseases. Anadis products provide immediate-acting, surface-based immune protection and hasten repair of damaged mucosa.

The all-natural platform, and its regulatory classification as food rather than as a biological or drug, allows for a significantly shorter timeframe from bench to market compared with typical biotechnology products. The platform also possesses dramatically lower manufacturing costs and higher scalability when compared with typical antibody-based solutions. The company is addressing existing market opportunities in excess of US \$30 billion.

Products include:

• Travelan, which significantly decreases the risk of the medical condition known as travellers' diarrhoea and the symptoms of gastrointestinal disorders caused by bacterially-contaminated food and water. Travelan has been launched and is available in several countries
• EVProtec a preventative product containing antibodies against Enterovirus 71, a virus which causes epidemics of a debilitating polio-like illness, as well as hand, foot and mouth disease, in Southeast Asia. The product is in the pre launch stage.

Research programs include:

• $\bullet$ The "Ectoplasm" Program A project in conjunction with Australian emergency response agencies developing a system for the containment and decontamination of hazardous materials.
• A set of Biodefence and Respiratory Protection technologies, focused on short-term immediate protection from airborne infections such as anthrax and plague.
• The Influenza Program utilising antibodies and their fragments as inhalants for the prevention $\bullet$ and treatment of influenza, including avian flu.

Bio-Shield 10 a range of "bio-shielding" technologies which shield orally administered proteins $\bullet$ from degradation during passage through the stomach. Initially targeted for use in the probiotic market, Bio-Shield 10 is the basis of a novel oral and respiratory tract delivery system being developed for the next generation of vaccines and therapeutic proteins.

ANADIS - Antibodies against Disease

Visit our websites: www.anadis.com.au and www.travelan.com